Pfizer, which is struggling to build traction for its Remicade biosimilar in the U.S., has some new data it hopes can make a difference in building sales for its Inflectra. More: Can Pfizer's new Crohn's data help Inflectra pry away
read moreMerck & Co. surprised investors and analysts Friday with news that it had pulled its European application for a new Keytruda combo in non-small cell lung cancer. They haven’t taken it well. More: Keytruda sales forecasts take a hit after
read moreShire intends to take some manufacturing of its rare disease drug Cinryze in house after problems with a contractor led to a shortage of the drug. The move comes even as Shire has targeted three more plants for elimination in
read moreMSD has pulled back its application to market Keytruda (pembrolizumab) in the European Union in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC). More: MSD pulls EU filing for Keytruda combo
read moreNovartis has unveiled plans to buy Advanced Accelerator Applications (AAA) for $3.9 billion in cash, beefing up its oncology portfolio. More: Novartis bolsters oncology offering with .9bn deal Source: News
read moreThe number of complaints to the Prescription Medicines Code of Practice Authority, which polices adherence to the Association of the British Pharmaceutical Industry’s Code of Practice, jumped significantly last year. More: 2016 saw jump in complaints to UK pharma regulator
read more© 1994 - 2026 B.M. Pharmaceuticals